In:
BJU International, Wiley, Vol. 121, No. 1 ( 2018-01), p. 69-76
Abstract:
To evaluate the role of caveolin‐1 (Cav‐1) as a predictor of disease reclassification ( DR ) in men with early prostate cancer undergoing active surveillance ( AS ). Patients and Methods We analysed archived plasma samples prospectively collected from patients with early prostate cancer in a single‐institution AS study. Of 825 patients enrolled, 542 had ≥1 year of follow‐up. Baseline and longitudinal plasma Cav‐1 levels were measured using an enzyme‐linked immunosorbent assay. Tumour volume or Gleason grade increases were criteria for DR . Logistic regression analyses were used to assess associations between clinicopathological characteristics and reclassification risk. Results In 542 patients, 480 (88.6%) had stage cT 1c disease, 542 (100.0%) had a median prostate‐specific antigen level of 4.1 ng/mL, and 531 (98.0%) had a median Cancer of the Prostate Risk Assessment score of 1. In all, 473 (87.3%) had a Gleason score of 3+3. After a median of 3.1 years of follow‐up, disease was reclassified in 163 patients (30.1%). The mean baseline Cav‐1 level was 2.2 ± 8.5 ng/mL and the median 0.2 ng/mL (range, 0–85.5 ng/mL). In univariate analysis, baseline Cav‐1 was a significant predictor for risk of DR (odds ratio [ OR ] 1.82, 95% confidence interval [ CI ] 1.24–2.65; P = 0.002). In multivariate analysis, with adjustments for age, tumour length, group risk stratification and number of positive cores, reclassification risk associated with Cav‐1 remained significant ( OR 1.91, 95% CI 1.28–2.84; P = 0.001). Conclusion Baseline plasma Cav‐1 level was an independent predictor of disease classification. New methods for refining AS and intervention may result.
Type of Medium:
Online Resource
ISSN:
1464-4096
,
1464-410X
DOI:
10.1111/bju.2018.121.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2019983-1
Permalink